Mesquida M, et al. - Researchers reported the 24-month efficacy and safety of the interleukin-6 receptor antagonist tocilizumab (TCZ) for refractory uveitis-related macular edema (ME) in this analysis. They obtained data by standardized chart review. They involved 16 eyes from 12 subjects (10 women). The findings demonstrated that when used for the treatment of refractory uveitis-related ME, TCZ was effective and had a comparable safety profile to published data for TCZ use in other indications.